Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Feb;13(2):229–232. doi: 10.1111/j.1365-2125.1982.tb01362.x

Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids.

D M Chambers, G C Jefferson, M Chambers, N B Loudon
PMCID: PMC1401993  PMID: 7059420

Abstract

1 A 'low-dose' combined oral contraceptive steroid (OCS) preparation containing 30 microgram ethinylo-estradiol and 150 microgram levonorgestrel was found to reduce significantly antipyrine clearance in a group of women acting as their own controls. 2 An OCS preparation containing only a progestogen (75 microgram norgestrel) did not reduce antipyrine clearance in a second group of women. 3 The evidence suggesting that the oestrogen component of combined OCS preparations could be responsible for the reduction in antipyrine clearance is discussed.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abernethy D. R., Greenblatt D. J. Impairment of antipyrine metabolism by low-dose oral contraceptive steroids. Clin Pharmacol Ther. 1981 Jan;29(1):106–110. doi: 10.1038/clpt.1981.17. [DOI] [PubMed] [Google Scholar]
  2. Carter D. E., Bressler R., Hughes M. R., Haussler M. R., Christian D., Heine M. W. Effect of oral contraceptives on plasma clearance. Clin Pharmacol Ther. 1975 Dec;18(6):700–707. doi: 10.1002/cpt1975186700. [DOI] [PubMed] [Google Scholar]
  3. Carter D. E., Goldman J. M., Bressler R., Huxtable R. J., Christian C. D., Heine M. W. Effect of oral contraceptives on drug metabolism. Clin Pharmacol Ther. 1974 Jan;15(1):22–31. doi: 10.1002/cpt197415122. [DOI] [PubMed] [Google Scholar]
  4. Chambers D. M., Jefferson G. C. Antipyrine estimations in the rabbit using gas--liquid chromatography: a reliable method for studying factors affecting oxidative drug metabolism. J Pharmacol Methods. 1981 Jan;5(1):59–66. doi: 10.1016/0160-5402(81)90103-0. [DOI] [PubMed] [Google Scholar]
  5. Dubois K. P., Kinoshita F. Modification of the anticholinesterase action of 0,0-diethyl 0-(4-methylthio-M-tolyl) phosphorothioate (DMP) by drugs affecting hepatic microsomal enzymes. Arch Int Pharmacodyn Ther. 1965 Aug;156(2):418–431. [PubMed] [Google Scholar]
  6. Fraser H. S., Mucklow J. C., Bulpitt C. J., Kahn C., Mould G., Dollery C. T. Environmental factors affecting antipyrine metabolism in London factory and office workers. Br J Clin Pharmacol. 1979 Mar;7(3):237–243. doi: 10.1111/j.1365-2125.1979.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fraser H. S., Mucklow J. C., Bulpitt C. J., Khan C., Mould G., Dollery C. T. Environmental effects on antipyrine half-life in man. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):799–808. doi: 10.1002/cpt1977225part2799. [DOI] [PubMed] [Google Scholar]
  8. Fraser H. S., Mucklow J. C., Murray S., Davies D. S. Assessment of antipyrine kinetics by measurement in saliva. Br J Clin Pharmacol. 1976 Apr;3(2):321–325. doi: 10.1111/j.1365-2125.1976.tb00610.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goble F. C. Sex as a factor in metabolism, toxicity, and efficacy of pharmacodynamic and chemotherapeutic agents. Adv Pharmacol Chemother. 1975;13:173–252. doi: 10.1016/s1054-3589(08)60232-x. [DOI] [PubMed] [Google Scholar]
  10. Herz R., Koelz H. R., Haemmerli U. P., Benes I., Blum A. L. Inhibition of hepatic demethylation of aminopyrine by oral contraceptive steroids in humans. Eur J Clin Invest. 1978 Feb;8(1):27–30. doi: 10.1111/j.1365-2362.1978.tb00804.x. [DOI] [PubMed] [Google Scholar]
  11. Homeida M., Halliwell M., Branch R. A. Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women. Clin Pharmacol Ther. 1978 Aug;24(2):228–232. doi: 10.1002/cpt1978242228. [DOI] [PubMed] [Google Scholar]
  12. Mackinnon M., Sutherland E., Simon F. R. Effects of ethinyl estradiol on hepatic microsomal proteins and the turnover of cytochrome P-450. J Lab Clin Med. 1977 Dec;90(6):1096–1106. [PubMed] [Google Scholar]
  13. Miller J. L., Clark C. R., Gee S. J., Krieger R. I. Antipyrine plasma half-life. In vivo indicator of oxidative metabolic capability in Rhesus monkeys (Macaca mulatta). Pharmacology. 1978;16(5):279–286. doi: 10.1159/000136780. [DOI] [PubMed] [Google Scholar]
  14. O'Malley K., Stevenson I. H., Alexander W. Increased antipyrine half-life in women taking oral contraceptives. Scott Med J. 1970 Dec;15(12):454–456. doi: 10.1177/003693307001501204. [DOI] [PubMed] [Google Scholar]
  15. O'Malley K., Stevenson I. H., Crooks J. Impairment of human drug metabolism by oral contraceptive steroids. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):552–557. doi: 10.1002/cpt1972134552. [DOI] [PubMed] [Google Scholar]
  16. Rautio A., Kauppila A. J., Tuimala R. J., Sotaniemi E. A. Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone. Biomedicine. 1979 Sep;31(5):135–138. [PubMed] [Google Scholar]
  17. Vesell E. S., Lee C. J., Passananti G. T., Shively C. A. Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs. Pharmacology. 1973;10(6):317–328. doi: 10.1159/000136453. [DOI] [PubMed] [Google Scholar]
  18. Vesell E. S., Passananti G. T., Glenwright P. A., Dvorchik B. H. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin Pharmacol Ther. 1975 Sep;18(3):259–272. doi: 10.1002/cpt1975183259. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES